A second experimental coronavirus vaccine being tested by Pfizer Inc and its German partner BioNTech SE showed promising results. About 77 percent of 18-to-55 year olds and 80 percent of adults aged 65 to 85 who received B1 reported mild to moderate reactions. Additionally, the authors note that the B1 vaccine was more likely to induce side effects such as fever, fatigue and chills, than B2. The team says that antibody levels were similar among patients who received either the B1 or B2 vaccine. Levels of IgG antibodies, which bind to the virus, and neutralizing antibodies were boosted by the second dose in younger participants, but less so in older participants.

Source: Daily Mail October 14, 2020 21:01 UTC